CTI BioPharma has initiated the rolling market application submission with the FDA to seek its approval for pacritinib as a treatment for patients with myelofibrosis who have severe thrombocytopenia. Pre-commercial activities have begun and planning is underway for a 2021 commercial launch, according to the company.
Rolling submission starts for CTI BioPharma's pacritinib
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.